BeiGene to Rebrand as BeOne Medicines With Oncology-Focused New Nasdaq Ticker "ONC"
BeiGene to Rebrand as BeOne Medicines With Oncology-Focused New Nasdaq Ticker "ONC"
BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))), a global oncology company that intends to change its name to BeOne Medicines Ltd., announced it will change its Nasdaq ticker symbol to "ONC" on January 2, 2025, reflecting its long-standing commitment to delivering innovative oncology medicines globally.
百濟神州有限公司（納斯達克股票代碼：BGNE，香港交易所：06160，證券交易所：688235））是一家打算更名爲BeOne Medicines Ltd. 的全球腫瘤公司，宣佈將於2025年1月2日將其納斯達克股票代碼更改爲 「ONC」，這反映了其在全球範圍內提供創新腫瘤藥物的長期承諾。
"As we enter our 15th year, changing our ticker to ONC reflects our unwavering commitment to leadership in oncology and mission to deliver transformative medicines to cancer patients worldwide," said John V. Oyler, Co-Founder, Chairman and CEO at BeiGene. "This milestone inspires pride in all we have accomplished and fuels our excitement for the future as we advance our innovative hematology franchise and solid tumor pipeline, driving meaningful impact for patients everywhere."
百濟神州聯合創始人、董事長兼首席執行官約翰·奧伊勒表示：「在我們進入第15個年頭之際，將股票代碼改爲ONC反映了我們對腫瘤學領導地位的堅定承諾以及爲全球癌症患者提供變革性藥物的使命。」「這一里程碑激發了我們對所取得的一切成就的自豪，也激發了我們對未來的興奮，因爲我們推進了創新的血液學特許經營權和實體瘤產品線，爲世界各地的患者帶來了有意義的影響。」
The Company's CUSIP number will remain unchanged. In addition, the Company stock codes and stock names for The Stock Exchange of Hong Kong and the STAR Market of the Shanghai Stock Exchange will not change. No action by the Company's shareholders is required to implement the Nasdaq ticker symbol change.
該公司的CUSIP號碼將保持不變。此外，香港聯合交易所和上海證券交易所科創板的公司股票代碼和股票名稱將保持不變。公司股東無需採取任何行動即可實施納斯達克股票代碼的變更。
